Alseres Pharmaceuticals (ALSE) Stock Price, News & Analysis

Company Overview

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson's disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

Key Stats

• Today's Range: $0.0050 to $0.0050
• 50-Day Range: $0.0050 to $0.0050
• 52-Week Range: $0.0050 to $0.0050
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALSE Stock Analysis - Frequently Asked Questions

How have ALSE shares performed this year?

Alseres Pharmaceuticals' stock was trading at $0.0050 on January 1st, 2025. Since then, ALSE shares have increased by 0.0% and is now trading at $0.0050.

How do I buy shares of Alseres Pharmaceuticals?

Shares of ALSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alseres Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alseres Pharmaceuticals investors own include Armata Pharmaceuticals (ARMP), Achillion Pharmaceuticals (ACHN), Aurora Cannabis (ACB), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP) and Advanced Biomedical Technologies (ABMT).

Company Calendar

• Today: 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ALSE
• CIK: N/A
• Web: www.alseres.com
• Phone: (617) 419-3289
• Fax: 508-497-9964
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A